109 Matching Annotations
  1. Aug 2022
    1. Vöhringer, H. S., Sanderson, T., Sinnott, M., De Maio, N., Nguyen, T., Goater, R., Schwach, F., Harrison, I., Hellewell, J., Ariani, C. V., Gonçalves, S., Jackson, D. K., Johnston, I., Jung, A. W., Saint, C., Sillitoe, J., Suciu, M., Goldman, N., Panovska-Griffiths, J., … Gerstung, M. (2021). Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 1–11. https://doi.org/10.1038/s41586-021-04069-y

  2. Apr 2022
    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. Prof Peter Hotez MD PhD. (2022, February 7). 1: BA.2 some evidence that it’s even more transmissible than the original omicron which is more transmissible than delta, and so forth. If it takes hold like it did in Denmark it will slow the descent of original omicron here [Tweet]. @PeterHotez. https://twitter.com/PeterHotez/status/1490669166176702466

  3. Mar 2022
  4. Feb 2022
    1. Lyngse, F. P., Mortensen, L. H., Denwood, M. J., Christiansen, L. E., Møller, C. H., Skov, R. L., Spiess, K., Fomsgaard, A., Lassaunière, M. M., Rasmussen, M., Stegger, M., Nielsen, C., Sieber, R. N., Cohen, A. S., Møller, F. T., Overvad, M., Mølbak, K., Krause, T. G., & Kirkeby, C. T. (2021). SARS-CoV-2 Omicron VOC Transmission in Danish Households (p. 2021.12.27.21268278). medRxiv. https://doi.org/10.1101/2021.12.27.21268278

    1. Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488

  5. Jan 2022
    1. Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.-V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2119912

    1. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw, D., Elliott, J., Whitaker, M., Walters, C., Atchison, C., Diggle, P., Page, A., Trotter, A., Ashby, D., Barclay, W., Taylor, G., Ward, H., Darzi, A., … Donnelly, C. (2022). Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 [Working Paper]. http://spiral.imperial.ac.uk/handle/10044/1/93887

  6. Dec 2021
    1. Seth Trueger. (2021, June 26). friendly reminder that “more transmissible” is by itself REALLY BAD for a pandemic. Even small increases in R₀ mean more potential for spread, more cases, more deaths etc please get your vax & help others get theirs https://t.co/mlojYmp71j [Tweet]. @MDaware. https://twitter.com/MDaware/status/1408811800108355586

    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  7. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. Prof. Christina Pagel. (2021, November 24). Meanwhile AY.4.2 (Delta grandchild) continues its very slow path to English dominance. Makes life a bit harder by being a bit more transmissible but luckily doesn’t seem any worse than Delta in any other respect. Https://t.co/kB0V0Z66GT [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1463508172941967365

    1. Dhar, M. S., Marwal, R., VS, R., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Bhatheja, N., Divakar, M. K., … Rakshit, P. (n.d.). Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science, 0(0), eabj9932. https://doi.org/10.1126/science.abj9932

  8. Oct 2021
  9. Sep 2021
    1. Twohig, K. A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M. A., Aliabadi, S., Seaman, S. R., Harris, R. J., Hope, R., Lopez-Bernal, J., Gallagher, E., Charlett, A., Angelis, D. D., Presanis, A. M., Dabrera, G., Koshy, C., Ash, A., Wise, E., Moore, N., … Gunson, R. (2021). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00475-8

  10. Aug 2021
    1. Prof. Christina Pagel on Twitter: “THREAD latest on B.1.617.2 variant in England: B.1.617.2 (1st discovered in India) is now dominant in England. Here is a thread summarising latest PHE report and Sanger local data. TLDR: it is NOT good news. 1/7” / Twitter. (n.d.). Retrieved August 24, 2021, from https://twitter.com/chrischirp/status/1399333330286415876

    1. Prof. Devi Sridhar. “Rest of the World Watching Closely: ‘In Scotland, Estimated That 92.5% of Adults Would Have Tested Positive for Antibodies against SARS-CoV-2 on a Blood Test in the Week Beginning 12 July 2021’- Is This Enough to Dampen Transmission & Protect under 12s from Infection? Under 18s?” Tweet. @devisridhar (blog), August 4, 2021. https://twitter.com/devisridhar/status/1422852550957617157.

  11. Jul 2021
    1. Carl T. Bergstrom. (2021, May 27). An update on the B.1.617.2 lineage. I’m concerned. Not because of reduced vaccine efficacy, but simply because a further increase in transmissibility above B.1.1.7 would be quite bad news for countries where vaccination is low and for hopes of near-elimination everywhere. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1398029743954432005

  12. Jun 2021
  13. May 2021
  14. Apr 2021
    1. Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., Drew, D. A., Nguyen, L. H., Polidori, L., Selvachandran, S., Hu, C., Capdevila, J., Koshy, C., Ash, A., Wise, E., … Ourselin, S. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. The Lancet Public Health, 0(0). https://doi.org/10.1016/S2468-2667(21)00055-4

  15. Mar 2021
  16. Feb 2021
  17. Sep 2020
  18. Aug 2020
  19. Jul 2020
  20. Jun 2020
  21. May 2020